The Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) drugs in development market research report provides comprehensive information on the therapeutics under development for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) by eight companies/universities/institutes. The top development phase for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) is phase ii with three drugs in that stage. The Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline products market are: Inovio Pharmaceuticals, Precigen and Merck.
The key targets in the Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline products market include Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor 2, and Vascular Endothelial Growth Factor Receptor 1.
The key mechanisms of action in the Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline product include Vascular Endothelial Growth Factor A Inhibitor with two drugs in Phase II. The Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline products include seven routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) pipeline products market including Monoclonal Antibody, and Small Molecule.
Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma) overview
Recurrent respiratory papillomatosis (RRP) or laryngeal papillomatosis (LP) is a benign mesenchymal neoplasm of the larynx in children. It is caused by human papilloma virus. Symptoms of RPV are dysphonia, stridor, respiratory distress, chronic cough, and snoring. Indirect fiberoptic laryngoscopy and direct laryngoscopy can be used for diagnosing RRP. HPV vaccine, antivirals, chemotherapy, and photodynamic therapy are the treatment options.
For a complete picture of Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
